Company profile
Aquestive Therapeutics, Inc.
NASDAQ:AQSTBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Diazepam | approved | — | 4 | approved |
| Ondansetron | phase1 | — | 4 | no active trials |
| RILUZOLE | phase1 | — | 3 | completed, terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07703982 | phase1 | completed | 2024-12-26 | 2025-03-14 | Aquestive Therapeutics | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of DESF in Pediatric Subjects |
| NCT03953820 | phase1_2 | completed | 2019-04-13 | 2019-07-31 | Aquestive Therapeutics | Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study |
| NCT06527937 | phase2 | completed | 2024-07-17 | 2024-10-10 | Aquestive Therapeutics | Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome |
| NCT03222349 | phase2 | completed | 2017-08-31 | 2020-01-28 | Aquestive Therapeutics | Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy |
| NCT03679975 | phase2 | terminated | 2018-04-04 | 2018-09-26 | Aquestive Therapeutics | Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS) |
FDA applications (4)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 022524 | NDA | AQUESTIVE THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 212640 | NDA | AQUESTIVE THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 212641 | NDA | AQUESTIVE | ||||
Loading… | ||||||
| NDA 218623 | NDA | AQUESTIVE | ||||
Loading… | ||||||